San Diego, California — According to state and local economic development sources Retrophin plans to invest $8,915,964.00 to build out 103,674 square feet of new space in San Diego. The company plans to occupy the new space at 3611 Valley Centre Dr Unit Flrs 2-5 in San Diego, on or about May 1, 2021. According to the company website At Retrophin, our mission is to identify, develop and deliver life-changing therapies to people living with rare diseases. We are a biopharmaceutical company focused on developing our pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options.

To learn more about Retrophin, visit http://www.retrophin.com/

Company Contact:
Eric Dube, Chief Executive Officer
https://www.linkedin.com/in/eric-dube-33160a12/
888-969-7879

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved